DDInter1938 DDInter484
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Vincristine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Vincristine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Vincristine {u} (Compound) downregulates {v} (Gene) EML3
EML3 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Vincristine {u} (Compound) upregulates {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Vincristine {u} (Compound) upregulates {v} (Gene) MAP7D1
MAP7D1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Vincristine {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Vincristine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) TUBB6
TUBB6 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Vincristine {u} (Compound) binds {v} (Gene) TUBB4B
TUBB4B {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Vincristine {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Vincristine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Vincristine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Vincristine (Compound) downregulates EML3 (Gene) and EML3 (Gene) is upregulated by Dasatinib (Compound)
Vincristine (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Dasatinib (Compound)
Vincristine (Compound) upregulates MAP7D1 (Gene) and MAP7D1 (Gene) is downregulated by Dasatinib (Compound)
Vincristine (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Dasatinib (Compound)
Vincristine (Compound) binds TUBB6 (Gene) and Vincristine (Compound) upregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Dasatinib (Compound)
Vincristine (Compound) binds TUBB4B (Gene) and TUBB4B (Gene) is downregulated by Dasatinib (Compound)
Vincristine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib